Antidyslipidemics - Branded Statin Market Facing Tough Times as Generics Thrive.

DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c41979) has announced the addition of Commercial Insight: Antidyslipidemics - Branded Statins Beware, Generics Are Amongst You to their offering. E[acute accent]Commercial Insight: Antidyslipidemics explores current trends and key future issues in the management of dyslipidemia and the effects of generic competition and healthcare reforms on the main drug classes in this market. E[acute accent]The growth potential of the leading classes is discussed, and case studies are used to highlight possible strategies to maximize future growth for lipid management franchises.

E[acute accent]Scope of this title:

E[acute accent]--Event-driven sales forecasts, for the period 2006-15, for the US, Japan, France, Germany, Italy, Spain and the UK, along with a global overview

E[acute accent]--Discussion of individual products in five main classes, focusing mainly on the statins, fibrates and other antidyslipidemics (e.g. Zetia, Niaspan)

E[acute accent]--Profiles of the country and market specific issues which will impact future sales in the market including generic erosion and new product launches

E[acute accent]--Commercial impact case studies on R&D innovation and the impact of generic erosion

E[acute accent]Highlights of this title:

E[acute accent]--2006 is likely to mark an inflexion point in the sales value of the statin class across the seven major markets (7MM). Key drivers of this include patent expiries to Zocor and Pravachol in the US, with a predicted $8 billion expected to be wiped off the value of the branded statin monotherapy market between 2006-11 as a result.

E[acute accent]--Strategies designed to blunt the impact of generic erosion on lipid management franchises include the development and commercialization of novel products. With further advances in LDL-C lowering efficacy unlikely, current research is focused on developing better tolerated and more effective HDL-C targeted therapies.

E[acute accent]--A growing in-licensing and acquisition trend has surfaced in lipid management and antiatherosclerotic R&D. As in-house productivity falls, big pharma has spent billions on shoring up product pipelines, focusing particular on novel HDL-C targeted therapies, which we believe is evolving into the new battleground in lipid management.

E[acute accent]Reasons to order your copy:

E[acute accent]--Gain insight into the antidyslipidemics market via up-to-date thought-leader opinions and gold-standard IMS Health sales data

E[acute accent]--Assess the potential impact of clinical trial results, generic erosion and new product launches on the antidyslipidemics market

E[acute accent]--Access independent, event-driven forecasts for key antidyslipidemic products and classes across the seven major markets

E[acute accent]For more information visit http://www.researchandmarkets.com/reports/c41979

E[acute accent]Source: Datamonitor